Amgen Inc
AMGN#125 of 134 by buybacksNASDAQ · Healthcare · Drug Manufacturers - General · USA
amgen.comBuybacks · FY2025$0latest fiscal year
Buyback yield0.0%repurchases ÷ market cap
Dividends · FY2025$5.12Bdividend yield 2.3%
Shareholder yield2.3%buybacks + dividends ÷ market cap
Shares outstanding · 5 yr−3.7%544M shares (2026)
Buybacks ÷ free cash flow0%payout incl. dividends 63%
Fiscal-year detail
From the cash-flow statement as reported, in USD. Negative repurchases mean net share issuance.
| Fiscal year | Repurchases | Dividends | Free cash flow |
|---|---|---|---|
| FY2025Dec 2025 | $0 | $5.12B | $8.10B |
| FY2024Dec 2024 | $200M | $4.83B | $10.4B |
| FY2023Dec 2023 | $0 | $4.56B | $7.36B |
| FY2022Dec 2022 | $6.36B | $4.20B | $8.79B |
| FY2021Dec 2021 | $4.97B | $4.01B | $8.38B |
| FY2020Dec 2020 | $3.49B | $3.75B | $9.89B |
| FY2019Dec 2019 | $7.70B | $3.51B | $8.53B |
Repurchases in FY2025 were −100.0% versus the prior year.
About Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction,…
- Market cap
- $224B
- P/E (trailing)
- 25.8×
- Fiscal year end
- December
- ISIN
- US0311621009
- Reporting currency
- USD
- Data updated
- Oct 10, 2026